Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
Abstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pem...
| Үндсэн зохиолчид: | , , , , , , , , , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Wiley
2023-12-01
|
| Цуврал: | Journal of Diabetes Investigation |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1111/jdi.14076 |
| _version_ | 1827629913949077504 |
|---|---|
| author | Tsutomu Hirano Toshiyuki Hayashi Hiroe Sugita Atsuko Tamasawa Satoshi Goto Masako Tomoyasu Takeshi Yamamoto Makoto Ohara Michishige Terasaki Hideki Kushima Yasuki Ito Sho‐ichi Yamagishi Yusaku Mori |
| author_facet | Tsutomu Hirano Toshiyuki Hayashi Hiroe Sugita Atsuko Tamasawa Satoshi Goto Masako Tomoyasu Takeshi Yamamoto Makoto Ohara Michishige Terasaki Hideki Kushima Yasuki Ito Sho‐ichi Yamagishi Yusaku Mori |
| author_sort | Tsutomu Hirano |
| collection | DOAJ |
| description | Abstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pemafibrate or increasing statin doses would more effectively reduce sdLDL‐C levels in patients receiving statin therapy. Materials and Methods A total of 97 patients with type 2 diabetes and hypertriglyceridemia who were treated with statins were randomly assigned to the pemafibrate 0.2 mg/day addition or statin dose doubled, and followed for 12 weeks. sdLDL‐C was measured by our established homogenous assay. Results The percentage and absolute reductions of sdLDL‐C levels were significantly greater in the pemafibrate add‐on group than the statin doubling group (−32.8 vs −8.1%; −16 vs −3 mg/dL, respectively). Triglyceride levels were reduced only in the pemafibrate add‐on group (−44%), and LDL‐C levels were reduced only in the statin doubling group (−8%), whereas levels of non‐high‐density lipoprotein‐C and apolipoprotein B were similarly decreased (7–9%) in both groups. The absolute reductions of sdLDL‐C levels were closely associated with decreased triglyceride, LDL‐C, non‐high‐density lipoprotein‐C and apolipoprotein B. In the subgroup analysis, the effect of pemafibrate add‐on on sdLDL‐C reductions was observed irrespective of baseline lipid parameters or statin type. No serious adverse effects were observed in both groups. Conclusions In patients with type 2 diabetes and hypertriglyceridemia, the addition of pemafibrate to a statin is superior to doubling a statin in reducing sdLDL‐C without increasing adverse effects. |
| first_indexed | 2024-03-09T13:59:03Z |
| format | Article |
| id | doaj.art-7b723e31cf984844b51b51d4814f39f0 |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-03-09T13:59:03Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-7b723e31cf984844b51b51d4814f39f02023-11-30T11:41:37ZengWileyJournal of Diabetes Investigation2040-11162040-11242023-12-0114121401141110.1111/jdi.14076Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapyTsutomu Hirano0Toshiyuki Hayashi1Hiroe Sugita2Atsuko Tamasawa3Satoshi Goto4Masako Tomoyasu5Takeshi Yamamoto6Makoto Ohara7Michishige Terasaki8Hideki Kushima9Yasuki Ito10Sho‐ichi Yamagishi11Yusaku Mori12Diabetes Center Ebina General Hospital Ebina JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanAsoka Hospital Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanClinical Diagnostics Department Denka Co., Ltd. Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine Showa University School of Medicine Tokyo JapanAbstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pemafibrate or increasing statin doses would more effectively reduce sdLDL‐C levels in patients receiving statin therapy. Materials and Methods A total of 97 patients with type 2 diabetes and hypertriglyceridemia who were treated with statins were randomly assigned to the pemafibrate 0.2 mg/day addition or statin dose doubled, and followed for 12 weeks. sdLDL‐C was measured by our established homogenous assay. Results The percentage and absolute reductions of sdLDL‐C levels were significantly greater in the pemafibrate add‐on group than the statin doubling group (−32.8 vs −8.1%; −16 vs −3 mg/dL, respectively). Triglyceride levels were reduced only in the pemafibrate add‐on group (−44%), and LDL‐C levels were reduced only in the statin doubling group (−8%), whereas levels of non‐high‐density lipoprotein‐C and apolipoprotein B were similarly decreased (7–9%) in both groups. The absolute reductions of sdLDL‐C levels were closely associated with decreased triglyceride, LDL‐C, non‐high‐density lipoprotein‐C and apolipoprotein B. In the subgroup analysis, the effect of pemafibrate add‐on on sdLDL‐C reductions was observed irrespective of baseline lipid parameters or statin type. No serious adverse effects were observed in both groups. Conclusions In patients with type 2 diabetes and hypertriglyceridemia, the addition of pemafibrate to a statin is superior to doubling a statin in reducing sdLDL‐C without increasing adverse effects.https://doi.org/10.1111/jdi.14076PemafibratesSmall dense low‐density lipoproteinType 2 diabetes |
| spellingShingle | Tsutomu Hirano Toshiyuki Hayashi Hiroe Sugita Atsuko Tamasawa Satoshi Goto Masako Tomoyasu Takeshi Yamamoto Makoto Ohara Michishige Terasaki Hideki Kushima Yasuki Ito Sho‐ichi Yamagishi Yusaku Mori Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy Journal of Diabetes Investigation Pemafibrates Small dense low‐density lipoprotein Type 2 diabetes |
| title | Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy |
| title_full | Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy |
| title_fullStr | Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy |
| title_full_unstemmed | Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy |
| title_short | Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy |
| title_sort | prospective randomized comparative study of the effect of pemafibrate add on or double statin dose on small dense low density lipoprotein cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy |
| topic | Pemafibrates Small dense low‐density lipoprotein Type 2 diabetes |
| url | https://doi.org/10.1111/jdi.14076 |
| work_keys_str_mv | AT tsutomuhirano prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT toshiyukihayashi prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT hiroesugita prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT atsukotamasawa prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT satoshigoto prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT masakotomoyasu prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT takeshiyamamoto prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT makotoohara prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT michishigeterasaki prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT hidekikushima prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT yasukiito prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT shoichiyamagishi prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy AT yusakumori prospectiverandomizedcomparativestudyoftheeffectofpemafibrateaddonordoublestatindoseonsmalldenselowdensitylipoproteincholesterolinpatientswithtype2diabetesandhypertriglyceridemiaonstatintherapy |